The observation that eIF4A inhibitor–based drug combinations simultaneously suppress the expression of multiple prosurvival proteins in these tumor cells is particularly important, given that different NSCLCs are thought to be dependent on different or multiple BCL-2 family members (28). The gene discussed is EIF4A1; the disease is neoplasm.